A widely used medication for type 2 diabetes is drawing new attention far beyond blood sugar control.

Researchers in the United Kingdom report that metformin, a drug prescribed to millions worldwide, may be linked to a lower risk of developing a key stage of age-related macular degeneration, a chronic eye condition that remains one of the leading causes of vision loss in older adults.

The findings have sparked interest among eye specialists and public health experts alike. Age-related macular degeneration, often referred to as AMD, affects the macula, the central part of the retina responsible for sharp, detailed vision. As populations age, the number of people living with this condition continues to rise. Any intervention that might delay or slow progression is therefore seen as potentially significant.

In the new analysis published in BMJ Open Opthalmology, scientists examined retinal images from around 2,000 people aged 50 and above who were living with diabetes and attending routine eye screening appointments. The screening programme, run through a major UK university and local health services, provided high-quality photographs collected over a five-year period. Researchers assessed whether signs of AMD were present and, if so, how advanced the disease appeared.

When the data were analysed, a striking pattern emerged. Participants who were taking metformin were significantly less likely to develop intermediate AMD than those who were not on the medication. The reduction in risk was estimated at about 37 per cent over the five years of observation. Intermediate AMD is a critical stage. It often precedes more severe disease and, in many cases, marks the point at which vision changes become noticeable and harder to reverse.

Scientists involved in the work described the findings as encouraging, especially given the limited treatment options currently available for early and intermediate forms of AMD. For many patients, management involves monitoring, lifestyle changes, and nutritional supplements rather than targeted drug therapy. The possibility that an existing, inexpensive medicine might offer some protection is therefore viewed as noteworthy.

At the same time, experts stress caution. The study was observational. It did not test metformin as a treatment for AMD, nor did it include people without diabetes. That distinction matters. Observational studies can reveal associations, but they cannot prove cause and effect. People who take metformin may differ in other important ways from those who do not. These differences can influence eye health independently of the drug itself.

Other large-scale research has produced more mixed results. A recent population-based study published in a major ophthalmology journal analysed health data from more than 1.6 million individuals. That work did not find a strong link between metformin use and a reduced risk of advanced AMD. Such contrasting findings underline the complexity of the disease and the challenge of identifying protective factors with certainty.

The careful assessment of retinal photographs over several years adds weight to the new analysis. However, the relatively small number of participants compared with national database studies means the results should be interpreted as preliminary. Most experts agree that randomised clinical trials would be needed before metformin could be recommended for AMD prevention or treatment.

There is also the question of generalisability. The participants in the UK study all had diabetes. It remains unclear whether similar effects would be seen in people without metabolic disease. Diabetes itself can affect the eyes in multiple ways, most notably through diabetic retinopathy. Separating the influence of diabetes, its treatments, and ageing on the retina is not straightforward.

Despite these uncertainties, the findings arrive at a time of growing interest in repurposing existing medicines. Metformin has been studied extensively for decades. Beyond diabetes, researchers have explored its potential roles in cardiovascular disease, cancer risk reduction, and even ageing-related processes. Laboratory studies suggest it may reduce inflammation and oxidative stress, both of which are thought to contribute to retinal degeneration.

Age-related macular degeneration develops gradually. In its early stages, many people notice little or no change in vision. As the disease progresses, symptoms can include difficulty seeing in low light, reduced contrast, and less vivid colours. Reading and recognising faces may become challenging. In advanced stages, central vision can be severely impaired, making everyday tasks difficult or impossible.

There are two main forms of the disease. Dry AMD is the most common, accounting for about 85 to 90 per cent of cases. It is characterised by the accumulation of small yellow deposits, known as drusen, beneath the retina. Wet AMD, though less common, is more aggressive. It involves the growth of abnormal blood vessels under the retina, which can leak fluid or blood and cause rapid vision loss.

Treatment options vary depending on the type and stage of AMD. For wet AMD, injections that block vascular growth factors have transformed care over the past two decades. These therapies can stabilise vision and, in some cases, improve it. For dry AMD, options are more limited. No cure exists, and approved treatments aim mainly to slow progression rather than restore lost vision.

One of the most established interventions for people with intermediate AMD is a specific vitamin and mineral supplement formulation. Known as AREDS2, it includes vitamins C and E, zinc, copper, lutein, and zeaxanthin. Large clinical trials have shown that this combination can reduce the risk of progression to advanced AMD by about 25 per cent. It does not prevent the disease, but it can make a meaningful difference for some patients.

Newer approaches are also emerging. Light-based therapies, including photobiomodulation, have recently gained regulatory approval in some regions for dry AMD. These treatments aim to support retinal cell function and reduce inflammation. Their long-term benefits are still being studied, but they reflect the growing effort to expand options beyond supplements and observation.

Always consult your healthcare providers for the best intervention.

Against this backdrop, interest in metformin is understandable. The drug is taken orally, has a long safety record, and is inexpensive. It works primarily by reducing glucose production in the liver, improving insulin sensitivity, and limiting glucose absorption from the gut. Unlike newer diabetes medications, it is not approved for weight loss, although modest weight reduction can occur.

Metformin is generally well tolerated. The most common side effects involve the digestive system, including nausea, diarrhoea, and indigestion. A rare but serious complication, lactic acidosis, has led to a formal safety warning. This risk is higher in people with significant kidney disease or other conditions that affect metabolism.

Because metformin lowers blood glucose, prescribing it to people without diabetes raises concerns. Low blood sugar, or hypoglycaemia, can cause dizziness, confusion, and in severe cases, loss of consciousness. Eye specialists caution strongly against using the drug off-label for AMD outside a clinical trial setting.

Public health guidance remains unchanged. Experts emphasise that people concerned about macular degeneration should focus on proven strategies. Regular eye examinations are essential, particularly for adults over 50 or those with a family history of AMD. Early detection allows for closer monitoring and timely intervention if the disease progresses.

Lifestyle factors also play a role. Avoiding tobacco smoke is one of the most important steps, as smoking is a well-established risk factor for AMD. Wearing sunglasses or a wide-brimmed hat can reduce cumulative exposure to ultraviolet light. Diet matters too. Patterns such as the Mediterranean diet, rich in vegetables, fruits, fish, and healthy fats, have been linked to better eye health.

Physical activity supports overall vascular health, which in turn benefits the eyes. Managing chronic conditions such as hypertension and diabetes is equally important. The retina is highly sensitive to changes elsewhere in the body. What protects the heart and brain often protects vision as well.

For people already taking metformin for diabetes, the new findings offer a note of cautious optimism. Continuing the medication for its approved purpose remains reasonable, and any potential eye benefits would be an added bonus rather than a guarantee. Expectations, however, should remain realistic.

Researchers involved in the UK study are now calling for clinical trials that directly test metformin in people with or at risk of AMD. Such trials would need to include diverse populations and carefully monitor visual outcomes over time. Only then could firm conclusions be drawn about its role in eye care.

Until that evidence emerges, evidence agree on one point. Metformin should not be viewed as a standalone solution for age-related macular degeneration. It is a promising lead, not a proven therapy. The story, like the disease itself, is still unfolding.